EstoniaTuberculosis profile
Population  2015 1.3 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.025 (0.025–0.025) 1.9 (1.9–1.9)
Mortality (HIV+TB only) <0.01 (<0.01–0.015) 0.25 (0–1.2)
Incidence  (includes HIV+TB) 0.24 (0.2–0.27) 18 (15–21)
Incidence (HIV+TB only) 0.024 (0.021–0.028) 1.8 (1.6–2.1)
Incidence (MDR/RR-TB)** 0.071 (0.05–0.092) 5.4 (3.8–7)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.016 (0.014–0.018) 0.051 (0.023–0.079) 0.067 (0.038–0.097)
Males 0 (0–0) 0.17 (0.13–0.2) 0.17 (0.13–0.2)
Total 0.016 (0.013–0.02) 0.22 (0.2–0.24) 0.24 (0.2–0.27)
TB case notifications, 2015  
Total cases notified 217
Total new and relapse 206
          - % tested with rapid diagnostics at time of diagnosis 73%
          - % with known HIV status 96%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 87%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (76–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.09–0.16)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 23 12%
          - on antiretroviral therapy 21 91%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  47
(36–59)
Estimated % of TB cases with MDR/RR-TB 16% (10–23) 54% (37–71)  
% notified tested for rifampicin resistance 84% 87% 184
MDR/RR-TB cases tested for resistance to second-line drugs   37
Laboratory-confirmed cases MDR/RR-TB: 43, XDR-TB: 9
Patients started on treatment **** MDR/RR-TB: 34, XDR-TB: 9
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 194
Previously treated cases, excluding relapse, registered in 2014 100% 1
HIV-positive TB cases, all types, registered in 2014 71% 14
MDR/RR-TB cases started on second-line treatment in 2013 70% 44
XDR-TB cases started on second-line treatment in 2013 40% 10
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) <1
Funding source: 100% domestic,  international, <1% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data